Navigation Links
Mindray Medical International Announces Second Quarter 2008 Results
Date:9/3/2008

-- Company Maintains Full Year Guidance

SHENZHEN, China, Sept. 3 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide today announced its selected unaudited financial results for the second quarter ended June 30, 2008. During the quarter, Mindray successfully completed the acquisition of Datascope Corp.'s patient monitoring business. The financial results reported below include the results of operations of the patient monitoring business acquired from Datascope ("DPM") starting from May 1, 2008.

Highlights for Second Quarter 2008

-- Second quarter 2008 net revenues were US$145.7 million, an increase of

99.5% from US$73.0 million in the second quarter 2007.

-- Net revenues generated in international markets in the second quarter

2008 were US$87.8 million, an increase of 139.0% from US$36.7 million

in the second quarter 2007.

-- Net revenues generated in China in the second quarter 2008 were US$57.9

million, an increase of 59.4% from US$36.3 million in the second

quarter 2007.

-- Non-GAAP operating profit, as defined below, in the second quarter 2008

was US$40.0 million, a 68.5% increase from US$23.7 million in the

second quarter 2007. Second quarter 2008 GAAP operating profit was

US$27.8million.

-- Second quarter 2008 non-GAAP net income, as defined below, was US$35.2

million, an increase of 54.7% from US$22.8 million in the second

quarter 2007. Second quarter 2008 GAAP net income was US$24.1 million.

-- Second quarter 2008 non-GAAP diluted earnings per share, as defined


'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
2. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
3. Mindray Medical International Announces Third Quarter 2007 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces First Quarter 2008 Results
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. BioMS Medical announces its intention to renew a normal course issuer bid

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...TERDAM, November 30 Biopharmaceuti... first patients have been enrolled in its,multinat...he study is,designed to show reduction in transpla...g an allogeneic stem cell transplantation with a m...patients eligible for an allogeneic,stem cell tran...
(Date:11/30/2009)...LE, Md., Nov. 30 Novavax...pleted enrollment in the Phase II clinical study o...mmended strains) VLP vaccine candidate in healthy ...his randomized, double-blind, active-controlled st...nogenicity of two different doses (15 mcg and 60 m...
(Date:11/30/2009)...ATTLE, Nov. 30 Cell Ther...ced today that its new class of platinum-based ant...ated a stronger anti-tumor potency and activity co...unds as well as the ability to overcome cisplatin-... presented in a paper titled "Novel Bis-platinum C...
(Date:11/30/2009)... LONDON, November 30 ApaTech, ...med Europe,s fastest growing,Biotech/Pharmaceutica...itte,2009 Technology Fast 500 for EMEA (Europe, Mi...ing is based on a companies, five-year revenue gro...8% over this period. This,achievement places ApaTe...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
... PALO ALTO, Calif., Jan. 7 Intradigm Corporat... interference (RNAi) therapeutics, today,announced...its Series B,financing. Astellas Venture Managemen...stor, Lilly Ventures, also participating. The add...ancing to $21.4 million. Intradigm will,use Serie...
... UNION CITY, Calif., Jan. 7 Abaxis, Inc. (Nasdaq:...g point-of-care blood analysis instruments for bot...day that it has entered into a license agreement f...nimal health diagnostics in the professional marke...ral flow immunoassay devices and methods. , , Thi...
... TAMPA BAY, Fla., Jan. 7 News briefs concerni...egion from the Tampa Bay Partnership: , Draper... The Charles Stark Draper Laboratory bought a 41...ly where it plans to manufacture microchips for th...th St. N., should be completed,in March 2009. The...
Other Biology Technology:Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 2Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 4
(Date:11/30/2009)...30, 2009) Scientists and engineers from two of th... will come together Dec. 7 with leading academici...ping blood. , Much like moving oil through a pip... Both systems need clean, well-functioning pipes ..., to function efficiently. Both industries also ar...
(Date:11/30/2009)...invasion proteins are crucial for infection. Each ...cells, which stimulates the host cell to take up t...ert a different function, for example the regulati...esults have now been published in the current issu...iled meat is one of the sources for Listeria inf...
(Date:11/30/2009)...le to HIV research is the virus,s exquisite specia...ts, traditional tools, like the humble lab mouse, ...of researchers writing in BioMed Central,s open ac...ssault on this problem by creating a mouse that ha...cted with HIV. , George Kassiotis, from the Divi...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3It takes 2 to infect 2A reductionist approach to HIV research 2Cancer Drug May Fight Alzheimers 56418 1Wellmont HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 56416 1Wellmont HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 56416 2Wellmont HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 56416 3Wellmont HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 56416 4Wellmont HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 56416 5Reportlinker Adds Lung Cancer Therapeutics Report 56414 1Reportlinker Adds Lung Cancer Therapeutics Report 56414 2Reportlinker Adds Lung Cancer Therapeutics Report 56414 3Reportlinker Adds Lung Cancer Therapeutics Report 56414 4Reportlinker Adds Lung Cancer Therapeutics Report 56414 5Reportlinker Adds Lung Cancer Therapeutics Report 56414 6Reportlinker Adds Lung Cancer Therapeutics Report 56414 7Reportlinker Adds Lung Cancer Therapeutics Report 56414 8Reportlinker Adds Lung Cancer Therapeutics Report 56414 9Reportlinker Adds Lung Cancer Therapeutics Report 56414 10
...e is available in German . , For quite some t...o been considered the building material of choice ...drowski at the Ruhr University in Bochum has now m...surfaces) from DNA building blocks. As reported in...formed in a self-assembly process from 20 individu...
...ethanol production has increased dramatically in r... increased. New U.S. government policies require m... plans call for a viable cellulosic ethanol indust... further growth of corn acres in the near term, wi...ently, U.S. grain-based ethanol production is conc...
...ftware Is Force Multiplier for Shelbyville Police ...tional,Inc. (OTC Bulletin Board: BKYI), a leader i...ss public safety solutions, today announced the,aw...Department,("Department") for the Department,s fir...e, BIO-key,s wireless messaging and query solution...
Other Biology News:Nano-softball made of DNA 2Fueling ethanol production while protecting water quality 2Fueling ethanol production while protecting water quality 3BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 2BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 3
EDG-1 Western blot control from Exalpha Biologicals, Inc.
Stem Cell Expansion Media 1 from 3H Biomedical AB
Human TIMP-1 ELISpot Development Kit from R&D Systems
BD IMagnet 1 each from BD Biosciences Pharmingen
Biology Products: